Tau as a biomarker of neurodegeneration
Journal Title
International Journal of Molecular Sciences
Abstract
Less than 50 years since tau was first isolated from a porcine brain, its detection in femtolitre concentrations in biological fluids is revolutionizing the diagnosis of neurodegenerative diseases. This review highlights the molecular and technological advances that have catapulted tau from obscurity to the forefront of biomarker diagnostics. Comprehensive updates are provided describing the burgeoning clinical applications of tau as a biomarker of neurodegeneration. For the clinician, tau not only enhances diagnostic accuracy, but holds promise as a predictor of clinical progression, phenotype, and response to drug therapy. For patients living with neurodegenerative disorders, characterization of tau dysregulation could provide much-needed clarity to a notoriously murky diagnostic landscape.
Publisher
MDPI
Keywords
Alzheimer’s disease; biomarker; cerebrospinal fluid; neurodegeneration; tau; tauopathy
Research Division(s)
Population Health And Immunity
PubMed ID
35806324
Open Access at Publisher's Site
https://doi.org/10.3390/ijms23137307
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2022-07-11 12:21:25
Last Modified: 2022-07-11 12:32:17
An error has occurred. This application may no longer respond until reloaded. Reload 🗙